Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Congressman Calls for Liberalized Access to Psilocybin; Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Positions for Growth Within Psychedelics Sector By: Investor Brand Network January 10, 2022 at 14:05 PM EST Congressman Earl Blumenauer recently wrote to his peers, urging them to petition the DEA to permit terminally ill patients to use psilocybin as part of their treatmentAlthough 41 states permit terminal patients to try investigational drugs, psilocybin continues to be banned by the DEAChange seems to be coming within the sector as evidenced by its decriminalization in cities such as Denver and OaklandDelic Corp has positioned itself as a leading psychedelic wellness platform, with business interests in ketamine infusion clinics, media, event management, and psilocybin research In mid-December, Representative Earl Blumenauer circulated an open letter to his colleagues in Congress, urging them to join him in petitioning the DEA to permit patients suffering from terminal illnesses to use psilocybin as part of their treatment, without fear of being federally prosecuted (https://ibn.fm/1NxQf). Although 41 U.S. states as well as Congress have adopted right-to-try laws, which permits patients with terminal illnesses to try investigational drugs that are yet to receive approval, the DEA has remained steadfast in its stance to… Read More>> NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF About PsychedelicNewsWire PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics. To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.PsychedelicNewsWire.com Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer Do you have questions or are you interested in working with PNW? Ask our Editor PsychedelicNewsWire (PNW)San Francisco, Californiawww.PsychedelicNewsWire.com415.949.5050 OfficeEditor@PsychedelicWire.com PsychedelicNewsWire is part of the InvestorBrandNetwork. Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
Congressman Calls for Liberalized Access to Psilocybin; Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Positions for Growth Within Psychedelics Sector By: Investor Brand Network January 10, 2022 at 14:05 PM EST Congressman Earl Blumenauer recently wrote to his peers, urging them to petition the DEA to permit terminally ill patients to use psilocybin as part of their treatmentAlthough 41 states permit terminal patients to try investigational drugs, psilocybin continues to be banned by the DEAChange seems to be coming within the sector as evidenced by its decriminalization in cities such as Denver and OaklandDelic Corp has positioned itself as a leading psychedelic wellness platform, with business interests in ketamine infusion clinics, media, event management, and psilocybin research In mid-December, Representative Earl Blumenauer circulated an open letter to his colleagues in Congress, urging them to join him in petitioning the DEA to permit patients suffering from terminal illnesses to use psilocybin as part of their treatment, without fear of being federally prosecuted (https://ibn.fm/1NxQf). Although 41 U.S. states as well as Congress have adopted right-to-try laws, which permits patients with terminal illnesses to try investigational drugs that are yet to receive approval, the DEA has remained steadfast in its stance to… Read More>> NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF About PsychedelicNewsWire PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics. To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.PsychedelicNewsWire.com Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer Do you have questions or are you interested in working with PNW? Ask our Editor PsychedelicNewsWire (PNW)San Francisco, Californiawww.PsychedelicNewsWire.com415.949.5050 OfficeEditor@PsychedelicWire.com PsychedelicNewsWire is part of the InvestorBrandNetwork.
Congressman Earl Blumenauer recently wrote to his peers, urging them to petition the DEA to permit terminally ill patients to use psilocybin as part of their treatmentAlthough 41 states permit terminal patients to try investigational drugs, psilocybin continues to be banned by the DEAChange seems to be coming within the sector as evidenced by its decriminalization in cities such as Denver and OaklandDelic Corp has positioned itself as a leading psychedelic wellness platform, with business interests in ketamine infusion clinics, media, event management, and psilocybin research In mid-December, Representative Earl Blumenauer circulated an open letter to his colleagues in Congress, urging them to join him in petitioning the DEA to permit patients suffering from terminal illnesses to use psilocybin as part of their treatment, without fear of being federally prosecuted (https://ibn.fm/1NxQf). Although 41 U.S. states as well as Congress have adopted right-to-try laws, which permits patients with terminal illnesses to try investigational drugs that are yet to receive approval, the DEA has remained steadfast in its stance to… Read More>> NOTE TO INVESTORS: The latest news and updates relating to DELCF are available in the company’s newsroom at https://ibn.fm/DELCF About PsychedelicNewsWire PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics. To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only) For more information please visit https://www.PsychedelicNewsWire.com Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer Do you have questions or are you interested in working with PNW? Ask our Editor PsychedelicNewsWire (PNW)San Francisco, Californiawww.PsychedelicNewsWire.com415.949.5050 OfficeEditor@PsychedelicWire.com PsychedelicNewsWire is part of the InvestorBrandNetwork.
